We believe that our long-term success in building an immuno-oncology franchise will be built upon toripalimab, an investigational PD-1 inhibitor, as a commercial point of entry into the rapidly growing immuno-oncology field. In conjunction with potentially commercializing toripalimab, we intend to develop PD-1 combination therapies, including our clinical-stage anti-TIGIT antibody candidate and our internal preclinical programs targeting immune-suppressive mechanisms in the tumor microenvironment, including ILT4.
